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Lipid rafts are cholesterol-enriched microdomains of the cell membrane and possess a highly dynamic nature. They have been
involved in various cellular functions including the regulation of cell adhesion and membrane signaling through proteins within
lipid rafts. The dynamic features of the cancer cell surface may modulate the malignant phenotype of cancer, including adhesion
disorders and aggressive phenotypes of migration and invasion. Recently, it was demonstrated that lipid rafts play critical roles in
cancercelladhesionandmigration.Thisarticlesummarizestheimportantrolesoflipidraftsincancercelladhesionandmigration,
with a focus on the current state of knowledge. This article will improve the understanding of cancer progression and lead to the
development of novel targets for cancer therapy.
1.Introduction
The alternation of cell adhesion and highly migratory behav-
ior are the most prominent features of cancer cells, and
play critical roles in their aggressive invasion and metastatic
spread [1]. These processes appear to be facilitated by re-
modelingoftheextracellularmatrix(ECM)ofthetumormi-
croenvironment and adhesion molecules at the cancer cell
surface and aﬀected by both the interaction between ECM
and adhesion molecules and by growth factor signaling [2,
3]. The proteolytic ectodomain cleavage and release (shed-
ding) of adhesion molecules are also critical regulatory steps
in cancer cell adhesion and migration [4, 5].
To date, cholesterol-enriched membrane microdomains
called“lipidrafts”havebeenimplicatedinavarietyofpatho-
geneses [6]; neurological diseases including Alzheimer’s [7],
Parkinson’s [8], and prion diseases [9]; cardiovascular dis-
eases; immune disorders such as systemic lupus erythemato-
sus [10] and HIV infection [11]. Lipid rafts have been also
implicated in signaling pathways in cancer progression [12],
but how these microdomains aﬀect the adhesion and migra-
tion of invasive cancer cells remains obscure. In this paper,
recent ﬁndings on the roles of lipid rafts in cancer cell adhe-
sion and migration will be reviewed.
2.LipidRaft Structure
The prevailing model of cellular membrane structure was
proposed by Singer and Nicolson, and this model is known
as the ﬂuid mosaic model, where globular proteins ﬂoat in
a lipid bilayer with a basic structure [13]. Later, the model
was improved by Simons and van Meer, who suggested the
existence of microdomains or “rafts” in the plasma mem-
brane of epithelial cells [14]. In the current understanding of
the lipid raft model, cholesterol- and sphingolipid-enriched
microdomains of the plasma membrane exhibit a biophys-
ical state comparable to the liquid-ordered phase ﬂoating
in the liquid-disordered phase of the membrane [15]. One
subtype of lipid rafts exists in ﬂask-shaped plasma mem-
brane invaginations called caveolae [16].
Lipid rafts consist of assemblies of cholesterol, sphin-
golipids including sphingomyelin and gangliosides, and cer-
tain types of proteins [15]. Sphingolipids contain saturated
fatty acyl chains in their structure, thereby allowing choles-
terol to be tightly intercalated in the sphingolipid assemblies
to form liquid-ordered microdomains. The most important
properties of lipid rafts are that they are small, dynamic,
and heterogeneous and can include or exclude proteins to
variable extents [17, 18]. Proteins with raft aﬃnity include2 International Journal of Cell Biology
glycosylphosphatidylinositol-anchored proteins, palmitoy-
lated proteins, doubly acylated proteins, such as Src family
kinases (SFKs), and transmembrane proteins such as CD44.
Lipid rafts have been implicated in various physiological
cellular processes, such as protein membrane traﬃcking and
signal transduction [18, 19].
3. Tools for LipidRaft Analyses
3.1. Lipid Raft Markers. Lipid rafts can be fractionated as
detergent-resistant membrane (DRM) fractions using non-
ionic detergents such as Triton X-100 [18, 20]. Cholesterol-
andsphingolipid-enrichedraftsareinsolubleinTritonX-100
at 4◦C and ﬂoat to a low-density area during gradient cen-
trifugation. Notably, the constitution of DRM is aﬀected
by the type and concentration of detergents, and lipid rafts
contained in DRM are nonnative aggregates. Marker mole-
culesforlipidraftsarefrequentlyusedinbiochemicalandcy-
tochemical analyses. The ganglioside GM1 is the most com-
monly used marker among putative lipid components of
rafts; it is detected using the GM1-binding molecule, cholera
toxin subunit B (CTxB) [21]. Protein markers such as cave-
olins and ﬂotillins are also used for identifying lipid rafts
[22].
3.2. Cholesterol Clathrate. Membrane cholesterol serves as
a spacer for the hydrocarbon chains of sphingolipids and
maintains the assembled microdomains of lipid rafts. Thus,
cholesterol depletion leads to the disorganization of lipid raft
structure. Methyl-β-cyclodextrin (MβCD), a torus-shaped
cyclic oligosaccharide composed of 7 d-glucopyranosyl units
linkedbyα-1,4glycosidicbonds,isusedtoextractmembrane
cholesterol selectively and to disrupt lipid rafts [23]. MβCD
is a practical tool for membrane studies as it neither binds
to nor inserts into the plasma membrane. MβCD-mediated
manipulation of membrane cholesterol is now a standard
methodology in the research of lipid rafts [18, 24]. However,
MβCD may deplete cholesterol from both the raft and non-
raft domains of the membrane as well as alter the distribu-
tion of cholesterol between the plasma membrane and
organelle membranes under high concentrations (i.e.,
>10mM). Thus, it is recommended that a cholesterol-reple-
tion experiment using cholesterol-MβCD complex and raft
disruption with other cholesterol-sequestering agents as des-
cribed below would be performed for conﬁrmation.
3.3. Cholesterol-Binding Antibiotics. Filipin, a ﬂuorescent
polyene macrolide antibiotic from Streptomyces ﬁlipinensis,
binds cholesterol and disperses it in the membrane. Filipin
is thus used as a cholesterol probe and a cholesterol seques-
trationagentintheresearchoflipidrafts[25,26].Otherthan
ﬁlipin, nystatin and amphotericin are also used in lipid-raft
analyses.
3.4. Inhibitors for Cholesterol Biosynthesis. Statins are widely
used inhibitors of 3-hydroxy-3-methylglutaryl-CoA reduc-
tase, the key rate-limiting enzyme in the biosynthesis of cho-
lesterol. Statins lower cellular cholesterol content and thus
are useful in the analysis of lipid-raft function. Prevention
studies using statins have conﬁrmed its signiﬁcance in the
prevention of cardiovascular diseases [27]. It has also been
demonstrated that statins may be an eﬀective preventive
medicineforneurodegenerativediseases,includingAlzheim-
er’s disease [28]. Although the various population-based
reports of the eﬀects of statins on cancer are controversial,
recent epidemiologic studies suggest that statins inhibit the
progression of certain cancers [29]. Recent evidence suggests
that statins blocked the adhesion and migration processes
of cancer cells [30, 31]. Cholesterol reduction is a potential
therapy for suppressing cancer cell adhesion and migration.
4.LipidRafts andProteolyticProcessingof
Adhesion Receptors
CD44 is a major cell adhesion molecule expressed in cancer
cells and implicated in cancer cell adhesion, migration, and
metastasis [32–34]. A number of reports have demonstrated
that CD44 is present in lipid rafts [35–40], but the role of
lipid rafts in cancer cell adhesion and migration has not been
elucidated.
Recently, it was demonstrated that lipid rafts play a cru-
cial role in the localization and functionality of CD44, which
regulates cancer cell adhesion and migration [31]. Treat-
ment of human glioma cells with the lipid-raft-disrupting
agent MβCD resulted in an increase in CD44 shedding
(Figure 1(a))[ 31]. Similar patterns are observed when cells
were treated with another lipid-raft-disrupting agent, ﬁlipin,
and also in the case of pancreatic cancer cells. Analyses of
Triton X-100 solubility of CD44 and its processing enzyme,
a disintegrin and metalloproteinase 10 (ADAM10), revealed
that CD44 was present in both Triton-X-100-insoluble and
Triton-X-100-soluble fractions of untreated cells, whereas
ADAM10 was largely in Triton-X-100-soluble fraction [30,
31] .T r e a t m e n tw i t hM βCD or ﬁlipin, however, led to loss
of CD44 from the Triton-X-100-insoluble fraction. These
results suggest that the perturbation of the ordered distri-
bution of CD44 and ADAM10 on the membrane increased
the probability of enzyme-to-substrate contact that leads to
enhanced CD44 shedding. Membrane microdomains such
as lipid rafts serve as platforms for the nanoscale assemb-
lyofmembraneproteins.Simvastatin,oneofthestatinsmost
frequently used in the clinical treatment of hypercholes-
terolemia, also enhanced CD44 shedding (Figure 1(b)).
Moreover, simvastatin blocked the stimulation of glioma
cell migration by hyaluronan oligosaccharides or epidermal
growth factor (EGF) (Figure 1(c))[ 41–43]. Taken together,
these results suggest that lowering cholesterol levels may
disturb the regulated CD44 membrane localization that is
necessary for enhanced cancer cell adhesion and migration
(Figure 2).
Recent studies on the shedding of various membrane
proteinsrevealedthatcholesteroldepletiontriggerstheshed-
dingofthesemolecules,including amyloidprecursorprotein
(APP) [44], IL-6 receptor [45], CD30 [46], L1-CAM [47],
and collagen types XVII [48] and XXIII [49]. It is especially
noteworthy that APP and CD30 were found to be strongly
associated with lipid rafts, whereas their processing enzymes,
ADAM10andADAM17,respectively,areexcludedfromlipidInternational Journal of Cell Biology 3
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Figure 1: Cholesterol lowering stimulates CD44shedding and suppresses cancer cell migration.(a) Modulation of cellular cholesterol aﬀects
CD44 shedding from human glioma cells. Cells were cholesterol-depleted (MβCD), cholesterol-replenished (MβCD/Chol), or left untreated
(control), and CD44 shedding was assessed by measurement of soluble CD44 in the culture medium. (b) Eﬀe c to fs i m v a s t a t i no nC D 4 4
shedding. Cells were incubated in the presence or absence of simvastatin, and CD44 shedding was assessed by measurement of soluble CD44
in the culture medium. (c) Eﬀect of simvastatin on CD44-dependent cell migration. Cells were incubated in the presence or absence of
simvastatin, and treated with hyaluronan oligosaccharides (o-HA) or EGF.
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Figure 2: A putative model of the lipid-raft-related cancer cell adhesion and migration.4 International Journal of Cell Biology
rafts [44, 46]. These ﬁndings suggest that lipid rafts may
play a critical role in regulating the accessibility of processing
enzymes to their substrate proteins during both constitutive
and regulated shedding [50].
Na+-H+ exchanger interacts with CD44 in lipid rafts and
may regulate cancer cell migration [39]. Complement com-
ponent receptor gC1qR is a lipid raft protein that is concen-
trated in the lamellipodia along with CD44, regulating A549
lung adenocarcinoma cell migration and metastasis [51].
5.CellAdhesion SignalinginLipidRafts
Integrins are transmembrane adhesion receptors composed
of α and β subunits that facilitate the anchorage of cells to
components of the ECM or bind to ligands on other cells
to support cell-cell adhesion. Recent evidence suggests that
the microorganization of lipids in the plasma membrane can
aﬀect integrin-mediated cellular functions [52]. Integrin-
mediated cell adhesion to the ECM is regarded as one of the
primary stages of SFKs’ function. SFKs are activated in lipid
rafts, and lipid-raft-speciﬁc inhibition of SFKs abrogates
adhesion of breast cancer cells [53]. The transmembrane
phosphoprotein, Cbp, a C-terminal Src kinase-binding pro-
tein, serves as a sensor of SFK activity in integrin-mediated
cell adhesion signaling [54].
CD44 is an important marker for various cancer stem
cells (CSCs), such as pancreatic [55], breast [56], ovarian
[57],colon[58],andbladderCSCs[59].However,whyCD44
is a CSC marker remains largely unknown. Recently, it was
reported that lipid-raft-associated CD44 is required for the
survival of CSCs in the suspension condition through CD44-
SFK-integrin signaling, leading to tumor metastasis [60].
Lipid rafts are necessary platforms for membrane re-
ceptor redistribution and the acquisition of a polarized phe-
notype during MCF-7 mammary adenocarcinoma cell mig-
ration [61]. Disruption of lipid rafts with MβCD abolishes
lamellipodia formation and inhibits the chemotactic migra-
tion of MCF-7 cells [61].
6. InvasionMachinery and LipidRafts
A variety of invasive cancer cells form invadopodia, sub-
cellular structures with ventral membrane protrusions that
induce ECM degradation, a pivotal process in cancer inva-
sion [62]. The ECM degradation activity of invadopodia
is mainly mediated by membrane type 1-matrix metal-
loproteinase (MT1-MMP) concentrated at the surface of
invadopodia [4]. Localization to lipid rafts is essential for
the internalization of MT1-MMP. Lipid rafts are required
for invadopodia formation in breast cancer cells and ECM
degradation [63]. Caveolin-1 is predominantly expressed
in invasive breast cancer cell lines and is well correlated
with invadopodia activity, implying that caveolin-1 plays
important roles in the traﬃcking of the components of
invadopodia including MT1-MMP [63].
ConcludingRemarks
I have summarized here the nature of lipid rafts and their
role in cancer cell adhesion and migration focusing on the
current state of knowledge, although many questions about
the nature of lipid rafts remain unsolved. Future studies may
corroborate a variety of aspects of the role of lipid rafts in the
regulation of adhesive and migratory properties of invasive
cancer cells.
The elucidation of the mechanism underlying the lipid-
raft-mediated regulation of cancer cell adhesion and migra-
tion will provide new insights into the mechanism of cancer
invasion and metastasis and also provide a wealth of new
targets for cancer prevention and therapy for clinical medi-
cine.
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